A Randomized, Double-Blind, Placebo-Controlled study to evaluate the effects of Alendronate (ALN) on bone mineral density (BMD) and bone remodeling in perimenopausal women with low BMD

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled study to evaluate the effects of Alendronate (ALN) on bone mineral density (BMD) and bone remodeling in perimenopausal women with low BMD

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2013

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2013 New trial record
    • 07 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top